These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31010434)

  • 1. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
    Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
    J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
    Snook AE; Baybutt TR; Hyslop T; Waldman SA
    Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
    Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
    Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
    Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
    Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
    Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
    Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
    Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
    J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
    Snook AE; Magee MS; Schulz S; Waldman SA
    Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GUCY2C-targeted cancer immunotherapy: past, present and future.
    Snook AE; Magee MS; Waldman SA
    Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.
    Abraham TS; Flickinger JC; Waldman SA; Snook AE
    J Immunol; 2019 Feb; 202(4):1301-1310. PubMed ID: 30642983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
    Snook AE; Stafford BJ; Li P; Tan G; Huang L; Birbe R; Schulz S; Schnell MJ; Thakur M; Rothstein JL; Eisenlohr LC; Waldman SA
    J Natl Cancer Inst; 2008 Jul; 100(13):950-61. PubMed ID: 18577748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
    Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
    Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
    Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
    PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
    Balint JP; Gabitzsch ES; Rice A; Latchman Y; Xu Y; Messerschmidt GL; Chaudhry A; Morse MA; Jones FR
    Cancer Immunol Immunother; 2015 Aug; 64(8):977-87. PubMed ID: 25956394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.